Aviva leaps on plans to slimline operations
Shares in Aviva leapt on Monday following reports which emerged over the weekend which are saying the insurance giant is set to sell or wind down between 10 and 15 of its 58 businesses.
Shares in Aviva leapt on Monday following reports which emerged over the weekend which are saying the insurance giant is set to sell or wind down between 10 and 15 of its 58 businesses.
No indication has been given as to which businesses will be targeted, although speculators have pointed towards the company reducing its stake in Dutch insurer Delta Lloyd and slimming down its US life business.
The news follows a strategic review, led by Chief Financial Officer, Patrick Regan, under which each business unit was rated based on its growth potential and return levels.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
The Telegraph has reported that many of the units are said to be considered "mediocre" in terms of their performance.
The changes will mean that the group is likely to suffer a decline in both profit and net asset value, although the company is likely to say in an upcoming presentation that a tangible increase in net worth will make this worthwhile.
Lord Colin Sharman on Monday retired as Chairman of the company and is being replaced by John McFarlane.
The share price rose 3.59% to 282.40p by 15:53.
NR
Sign up to Money Morning
Our team, led by award winning editors, is dedicated to delivering you the top news, analysis, and guides to help you manage your money, grow your investments and build wealth.
-
GSK share price surges after $2.2bn Zantac drug settlement
GSK has settled lawsuits in the US that alleged the drugmaker’s now-discontinued heartburn drug Zantac triggered cancer
By Chris Newlands Published
-
Will the Autumn Budget impact investment markets?
Keir Starmer has warned the Autumn Budget will be “painful”. Will it impact investment markets and should you tweak your portfolio before 30 October?
By Katie Williams Published